PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma
Advanced Science · 2025
DOI: 10.1002/advs.202504372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Mengzhou Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Ferroptosis, Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Laboratory of Diagnosis and Treatment of Severe Hepato-pancreatic Diseases of Zhejiang Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality worldwide. Ferroptosis, an iron‐dependent form of programmed cell death driven by lipid peroxidation, has emerged as a promising strategy for cancer treatment. However, the development of ferroptosis resistance limits the efficacy of such treatments. This study reports that phosphatidylinositol 4‐phosphate 5‐kinase 1 alpha (PIP5K1A) promotes HCC tumorigenesis and predicts poor prognosis in HCC patients. Knockdown of PIP5K1A enhances lipid peroxidation and increases sensitivity to sorafenib‐induced ferroptosis by inhibiting the activation of downstream ferroptosis‐related genes regulated by nuclear factor erythroid‐2‐related factor 2 (NRF2). Mechanistically, PIP5K1A competitively binds to the Kelch domain of Kelch‐like ECH‐associated protein 1 in a kinase‐independent manner, leading to NRF2 escaping from ubiquitination degradation, thereby promoting NRF2‐dependent transcription and suppressing ferroptosis. Furthermore, ISA‐2011B, a PIP5K1A‐specific inhibitor, effectively inhibits HCC growth and sensitized HCC cells to sorafenib. In conclusion, PIP5K1A is a promising therapeutic target for improving the efficacy of sorafenib and other ferroptosis inducers in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
- Liver Cancer Institute and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
- Department of Gastroenterology and Hepatology and Shanghai Institute of Liver Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
- Department of Liver Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
ORCID-Profile: Mengzhou Guo, Jinglin Xia
Förderung
- National Natural Science Foundation of China
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-pancreatic Diseases of Zhejiang Province
Zitieren
APA
Guo, M., Chen, S., Sun, J., Xu, R., Qi, Z., Li, J., Zhou, L., Fang, Y., Liu, T., & Xia, J. (2025). PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202504372
Vancouver
Guo M, Chen S, Sun J, Xu R, Qi Z, Li J, et al. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202504372
BibTeX
@article{Guo2025,
author = {Guo, Mengzhou and Chen, Sinuo and Sun, Jialei and Xu, Ruchen and Qi, Zhuoran and Li, Jie and Zhou, Lianer and Fang, Yuan and Liu, Tianshu and Xia, Jinglin},
title = {PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202504372}
}
EUVIMED